Pacific Bio (NASDAQ: PACB) reported Q2 EPS of ($0.17), in-line with the analyst estimate of ($0.17). Revenue for the quarter came in at $21.6 million versus the consensus estimate of $23.79 million.

For earnings history and earnings-related data on Pacific Bio (PACB) click here.